2. Academic Validation
  3. Chemotherapy resistance in acute myeloid leukemia is mediated by A20 suppression of spontaneous necroptosis

Chemotherapy resistance in acute myeloid leukemia is mediated by A20 suppression of spontaneous necroptosis

  • Nat Commun. 2024 Oct 24;15(1):9189. doi: 10.1038/s41467-024-53629-z.
Ashley E Culver-Cochran 1,  Aishlin Hassan 1,  Kathleen Hueneman 1,  Kwangmin Choi 1,  Averil Ma 2,  Brett VanCauwenbergh 3,  Eric O'Brien 3,  Mark Wunderlich 1,  John P Perentesis 3 4,  Daniel T Starczynowski 5 6 7 8
Affiliations

Affiliations

  • 1 Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital, Cincinnati, USA.
  • 2 Department of Medicine, University of California, San Francisco, San Francisco, USA.
  • 3 Division of Oncology, Cincinnati Children's Hospital, Cincinnati, USA.
  • 4 Department of Pediatrics, University of Cincinnati, Cincinnati, USA.
  • 5 Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital, Cincinnati, USA. Daniel.Starczynowski@cchmc.org.
  • 6 Department of Pediatrics, University of Cincinnati, Cincinnati, USA. Daniel.Starczynowski@cchmc.org.
  • 7 Department of Cancer Biology, University of Cincinnati, Cincinnati, USA. Daniel.Starczynowski@cchmc.org.
  • 8 University of Cincinnati Cancer Center, Cincinnati, USA. Daniel.Starczynowski@cchmc.org.
PMID: 39448591 DOI: 10.1038/s41467-024-53629-z
Abstract

Acute myeloid leukemia (AML) is a deadly hematopoietic malignancy. Although many patients achieve complete remission with standard induction therapy, a combination of cytarabine and anthracycline, ~40% of patients have induction failure. These refractory patients pose a treatment challenge, as they do not respond to salvage therapy or allogeneic stem cell transplant. Herein, we show that AML patients who experience induction failure have elevated expression of the NF-κB target gene tumor necrosis factor alpha-induced protein-3 (TNFAIP3/A20) and impaired necroptotic cell death. A20High AML are resistant to anthracyclines, while A20Low AML are sensitive. Loss of A20 in AML restores sensitivity to anthracycline treatment by inducing Necroptosis. Moreover, A20 prevents Necroptosis in AML by targeting the Necroptosis effector RIPK1, and anthracycline-induced Necroptosis is abrogated in A20High AML. These findings suggest that NF-κB-driven A20 overexpression plays a role in failed chemotherapy induction and highlights the potential of targeting an alternative cell death pathway in AML.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z